A team led by Brigham investigators has reported findings from a study looking at whether heart failure patients with mildly reduced or preserved ejection fraction could benefit from treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin. First author Scott David Solomon, MD, shares his perspective.

An international research team co-led by Christine E. Seidman, MD, found that molecular and cellular mechanisms of heart failure in patients with dilated cardiomyopathy or arrhythmogenic cardiomyopathy were determined by the specific gene variant each individual carried.

A potential cardiovascular benefit of vupanorsen would best be reflected by its effects on non–high-density lipoprotein cholesterol (non–HDL-C) and apolipoprotein B (ApoB). Brigham researchers studied vupanorsen at higher doses and observed significant reductions in non–HDL-C at all doses studied.

In a post hoc analysis of the PARAGON-HF trial, Scott D. Solomon, MD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital, and colleagues evaluated how atrial fibrillation and atrial flutter affected the results.

The REDUCE-IT trial found patients at risk had reduced important ischemic events with icosapent ethyl. Prakriti Gaba, MD, and Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital, and colleagues, conducted a post hoc analysis limited to patients in the trial who had a history of myocardial infarction (MI).

Brigham researchers have demonstrated that in an older population with normal ejection fraction and sinus rhythm, age‐related left atrium reservoir dysfunction and stiffness—detectable on three-dimensional echocardiography (3DE)—were associated with higher odds of subclinical cerebral infarcts (SCIs) and stroke.

Over the past decade in cardiac surgery, health policy initiatives have been implemented to reduce sex and socioeconomic status disparities. To evaluate progress in the U.S., researchers at Brigham and Women’s Hospital recently conducted the largest nationally representative study to date.